Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 7.25 Contact Hours.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Exelixis, Inc., Lilly, and Merck Sharp & Dohme Corp.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

4th Annual School of Gastrointestinal Oncology™ (SOGO®)

4th Annual School of Gastrointestinal Oncology™ (SOGO®)


Saturday, April 27, 2019
Grand Hyatt Washington
1000 H Street NW
Washington, DC 20001
https://washingtondc.grand.hyatt.com/en/hotel/home.html

4th Annual School of Gastrointestinal Oncology® (SOGO™®) Overview

PER’s practice changing 4th Annual School of Gastrointestinal Oncology® (SOGO™®) is a 1-day multidisciplinary educational conference, revolutionizing the presentation of emerging therapies and evolving standards of care in the management of patients with gastrointestinal (GI) tumors in the context of the program theme, to individualize care.

GI cancers are some of the most complex solid tumors to treat because of their heterogeneity. Optimized management requires a high level of multidisciplinary cooperation. The rapid pace of emerging developments creates knowledge and competence gaps for you and your colleagues who treat, manage, and care for patients with GI cancers.

Led by world-renowned experts John L. Marshall, MD, and Michael A. Choti, MD, MBA, FACS, this multi-track symposium, now in its fourth year, will provide you with the tools you need to personalize care for every patient with GI cancer you treat. The program will include various modules that feature general session  presentations on key learning concepts, along with separate side tracks to provide a workshop sensibility to personalize learning in smaller and more intimate settings. With 3 tracks—locoregional GI cancers, advanced GI cancers, and case discussion—the program is designed to match your learning interests.

This year’s symposium will once again feature the dynamic and interactive Medical Crossfire® format, where experts will engage in a rigorous debate to answer your questions, and reach consensus on ongoing paradigm shifts. The program will focus on the latest data on prognostic and predictive markers that impact clinical decision making, current and emerging treatment strategies, and case-based lectures by expert faculty who will focus on the practical application of knowledge to the complex care scenarios encountered in contemporary practice settings. Physicians’ Education Resource® (PER®) will continue to use its proven educational modalities to ensure a highly interactive meeting that fosters discussion and exchange of ideas, best practices, and cross-team cooperation in the clinic. This will include case-based tumor boards, question-and-answer sessions, ARS polling, and networking opportunities.

“The evolution of treating patients who have gastrointestinal (GI) cancers has really transformed over the past few years and will continue to do so moving forward. We know that personalizing disease in these tumors has to be done, and we need to involve the entire clinical team to do so. The expanded role of immune therapies, the importance of multidisciplinary care, and the role of precision medicine has further complicated the pathways of care. With all the advances that have been made in both treatment and care management, we have turned GI cancer into a chess game, and we need to make sure all the players and pieces are working together. This meeting will continue to education the treatment team through multiple presentations and small group discussions and will truly be the most unique GI cancers meeting around.”

— John Marshall, MD
Ruesch Center for the Cure of GI Cancers
Georgetown University Medical Center

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Exelixis, Inc., Lilly, and Merck Sharp & Dohme Corp.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Target Audience

This educational program is directed toward oncologists and gastroenterologists whose primary practice focus is GI cancers, and who intend to reinforce their knowledge base and expand their expertise in GI diagnosis, risk stratification, personalization of care, and best practices for multidisciplinary communication. Participants will be primarily oncologists, gastroenterologists, or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of GI cancers.

Learning Objectives

  • Discuss patient-related and tumor-related biomarkers and prognostic factors relevant to patient risk stratification to inform clinical decision-making
  • Describe the most relevant clinical data from pivotal trials to inform personalized clinical decision-making and multidisciplinary practice
  • Assess strategies for the recognition, mitigation, and management of potential adverse events and toxicities associated with therapies for GI tumors
  • Outline best practice for management of patients through specific case discussions focusing on the latest updates in GI cancer management

4th Annual School of Gastrointestinal Oncology® (SOGO™®) Program Co-Chairs

John Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Chief, Hematology and Oncology
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC

Michael A Choti, MD, MBA, FACS
Chief of Surgery
Banner MD Anderson Cancer Center
Phoenix, AZ






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By